New old drug(s) for spinocerebellar ataxias

Affiliations

Comment

Visou Ady et al. J Physiol. 2017.

. 2017 Jan 1;595(1):5-6.

doi: 10.1113/JP273149.

No abstract available

Figures

Progressive impairment of cerebellar mGluR signalling and its therapeutic potential for cerebellar ataxia in spinocerebellar ataxia type 1 model mice.
Shuvaev AN, Hosoi N, Sato Y, Yanagihara D, Hirai H. Shuvaev AN, et al. J Physiol. 2017 Jan 1;595(1):141-164. doi: 10.1113/JP272950. Epub 2016 Sep 15. J Physiol. 2017. PMID: 27440721 Free PMC article.

1. Dell'Orco JM, Wasserman AH, Chopra R, Ingram MA, Hu YS, Singh V, Wulff H, Opal P, Orr HT & Shakkottai VG (2015). Neuronal atrophy early in degenerative ataxia is a compensatory mechanism to regulate membrane excitability. J Neurosci 35, 11292–11307. - PMC - PubMed
1. Hirono M, Yoshioka T & Konishi S (2001). GABAB receptor activation enhances mGluR‐mediated responses at cerebellar excitatory synapses. Nat Neurosci 4, 1207–1216. - PubMed
1. Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d'Exaerde A, Cheron G, Orr HT, Pandolfo M & Schiffmann SN (2011). Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 31, 11795–11807. - PMC - PubMed
1. Jayabal S, Chang HHV, Cullen KE & Watt AJ (2016). 4‐aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6. Sci Rep 6, 29489. - PMC - PubMed
1. Meera P, Pulst SM & Otis TS (2016). Cellular and circuit mechanisms underlying spinocerebellar ataxias. J Physiol 594, 4653–4660. - PMC - PubMed